Identification of new oral dosing regimens for the neuraminidase inhibitor oseltamivir in patients with moderate and severe renal impairment

By  

Clinical Pharmacology In Drug Development, Vol. 2160-763X, Iss. 5, 2015-09 ,pp. : 326-336

John Wiley & Sons Inc

Access to resources Recommend Favorite

The dosing of anidulafungin does not require adjustment in patients with hepatic or renal impairment

By  

Inpharma, Vol. 1, Iss. 1585, 2007-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Different Synthetic Strategies of Oseltamivir Phosphate: A Potent Influenza Neuraminidase Inhibitor

By  

Current Medicinal Chemistry, Vol. 15, Iss. 30, 2008-12 ,pp. : 3145-3159

Bentham Science Publishers

Access to resources Recommend Favorite

Discovery and Development of GS 4104 (oseltamivir) An Orally Active Influenza Neuraminidase Inhibitor

By  

Current Medicinal Chemistry, Vol. 7, Iss. 6, 2000-06 ,pp. : 663-672

Bentham Science Publishers

Access to resources Recommend Favorite

Influence of Severe Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Ximelagatran and Subcutaneous Melagatran

By Eriksson U.G.  

Clinical Pharmacokinetics, Vol. 42, Iss. 8, 2003-01 ,pp. : 743-753

Adis International

Access to resources Recommend Favorite